Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:56 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer.
NCT05111626 · Amgen · PHASE3 · terminated · last registry update 2026-09-10 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Study was terminated by sponsor” | – | Registry record, Amgen |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against FGFR2 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-11-10Also stopped (terminated): National Institute of Dental and Craniofacial Research (NIDCR), BGJ398 (NCT03510455)
- 2026-11-03Also stopped (terminated): Peking University Cancer Hospital & Institute, KN046 + regorafenib (NCT05985109)
- 2026-10-20Also stopped (suspended): City of Hope Medical Center, Azacitidine + Regorafenib (NCT06454409)
- 2026-10-15Results posted on the registry: Rohit Aggarwal, MD, Nintedanib + Placebo (NCT05799755)
- 2026-10-05Also stopped (terminated): Children's Oncology Group, Cyclophosphamide + Doxorubicin Hydrochloride (NCT06820957)
- 2026-09-11Results posted on the registry: Memorial Sloan Kettering Cancer Center, Regorafenib (NCT02023333)
- 2026-09-02Results posted on the registry: Memorial Sloan Kettering Cancer Center, BGJ398 (NCT02657486)
- 2026-08-26Results posted on the registry: Bristol-Myers Squibb, Nivolumab-relatlimab FDC + Regorafenib (NCT05328908)
- 2026-08-26Also stopped (terminated): Bristol-Myers Squibb, Nivolumab-relatlimab FDC + Regorafenib (NCT05328908)
- 2026-08-19Also stopped (terminated): Boundless Bio, Inc., BBI-355 + Erlotinib (NCT05827614)
- 2026-08-13Results posted on the registry: PureTech, Nintedanib 150 MG [Ofev] (NCT06717100)
- 2026-08-11Results posted on the registry: Incyte Corporation, Pemigatinib + Gemcitabine (NCT03656536)
- 2026-08-11Also stopped (terminated): Incyte Corporation, Pemigatinib + Gemcitabine (NCT03656536)
- 2026-08-04Phase 3 first posted: UNICANCER, Futibatinib + Ivosidenib + Capecitabine (NCT07745296)
- 2026-07-28Phase 3 first posted: Sichuan Baili Pharmaceutical Co., Ltd., BL-M07D1 + Regorafenib (NCT07730489)
- 2026-07-23Phase 3 first posted: Innovent Biologics (Suzhou) Co. Ltd., IBI363 + bevacizumab + Investigator's choice of therapy (NCT07722494)
- 2026-07-22Results posted on the registry: Amgen, Sotorasib + Panitumumab (NCT05198934)
- 2026-07-20Results posted on the registry: Academic and Community Cancer Research United, Durvalumab + Regorafenib (NCT05194293)
- 2026-07-17Phase 3 first posted: Taiho Pharmaceutical Co., Ltd., Futibatinib + Zimberelimab (NCT07710885)
- 2026-07-06Results posted on the registry: Syndax Pharmaceuticals, Revumenib + Chemotherapy (NCT05731947)
- 2026-07-06Also stopped (terminated): Syndax Pharmaceuticals, Revumenib + Chemotherapy (NCT05731947)
- 2026-06-16Results posted on the registry: University of Southern California, Pembrolizumab + Regorafenib (NCT03657641)
- 2026-06-15Also stopped (withdrawn): University of Miami, Regorafenib (NCT06902246)
- 2026-06-10Results posted on the registry: Australasian Gastro-Intestinal Trials Group, Regorafenib + Nivolumab (NCT04879368)
- 2026-04-30Results posted on the registry: Icahn School of Medicine at Mount Sinai, Nintedanib + Placebo (NCT04619680)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision